Vyome Therapeutics

Vyome Therapeutics is an innovation-driven, clinical stage specialty pharmaceutical company, working to treat inflammatory diseases with locally-acting, next generation therapeutic solutions. Vyome's management team members are leaders in the drug development field, with deep expertise and a proven track record of successfully launching over 50 products in the life sciences and in building visionary companies. Vyome has a robust pipeline of novel locally-acting drug candidates designed to improve current standards of care for multifactorial diseases of unmet need which are underpinned by inflammation. The company's lead molecule (VB-1953), which targets the substantial unmet need in the drug resistant C. acne prescription market, is a powerful bactericidal topical treatment with the demonstrated ability to inhibit inflammatory cytokine production and reduce inflammatory lesions in acne. VB-1953 completed enrollment in its Phase 2b clinical trial in October 2019 with clinical results expected in the first half 2020. Vyome is also developing VT-1908 and VT-1917. VT-1908 is a locally-administered treatment for immune cell-mediated non-infectious uveitis. In preclinical studies, VT-1908 demonstrated the ability to reduce inflammation in the uvea of the eye through the inhibition of aberrant B and T cell activity and could potentially improve upon the current standard of care, eliminating the need for steroids. VT-1917 is a preclinical bactericidal and anti-inflammatory candidate optimized for local administration for otitic infections. Current standards of care are only able to address either the inflammatory or bacterial component of the disease, but VT-1917’s approach could shift the current treatment paradigm in otitic diseases by addressing both inflammation and bacterial infection with one locally-acting drug.